Browse studies

Find your next paid study

1,260 recruiting studies matching your filters

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in partici…

Non-small Cell Lung Cancer

Estimated

~$50 – $2,250

Actual pay is set by the research site.

Bristol-Myers SquibbNCT06561386

Observational

Leveraging Health Information Technology to Reduce Health Disparities in Adolescent Health Outcomes: A Patient-Centered Approach

We will conduct a randomized trial to compare differences in sexually transmitted infection (STI) treatment adherence between patients receiving text messages …

Sexually Transmitted Diseases

Estimated

~$10 – $675

Actual pay is set by the research site.

Children's National Research InstituteNCT04372485

Phase 1

A Phase Ib/II Study to Evaluate the Safety and Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Combination With Quemliclustat in Unresectable Locally Advanced and Metastatic Urothelial Carcinoma

This phase Ib/II trial tests the safety, side effects, and best dose of quemliclustat in combination with enfortumab vedotin and pembrolizumab, and to see how …

Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial Carcinoma+10 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Phase 1

A Phase I, Single-Center, Dose Escalation Trial of Heterologous Prime-Boost Vaccination With Ad5.F35-hGUCY2C-PADRE and Lm-GUCY2C Vaccines in Adults With Advanced Colorectal and Small Bowel Adenocarcinomas

This is an open-label, non-randomized, single-center, dose-escalation Phase 1 trial using a heterologous prime-boost strategy of vaccination with Ad5.F35-hGUCY…

Colorectal CancerSmall Bowel Adenocarcinoma

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Thomas Jefferson UniversityNCT07417488

Phase 1

A Phase 1b Study of Tocilizumab Combined With Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients With Cancer-Associated Weight Loss and Elevated Inflammatory Markers. The TOCI Study

This is a Phase 1b/2, multi-site, single-arm, open-label, non-randomized study looking at whether adding tocilizumab to standard treatment for metastatic Non-S…

Metastatic Non-Small Cell Lung CancerCancer-Associated Weight LossElevated Inflammatory Markers

Estimated

~$150 – $2,700

Actual pay is set by the research site.

VA Office of Research and DevelopmentNCT07889232

Phase 1

A Phase I Trial for R/R MetAstatic DLL3+ Cancers Utilizing Armored CAR T Cells (ARMADA)

The purpose of this study is to test the safety of DLL3-SAVVYZ-IL18 in people with DLL3+ cancer.

Neuroendocrine CancerSmall Cell Lung CancerSmall Cell Lung Cancer ( SCLC )

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT07783477

Phase 2

A Phase 2 Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Treatment-Experienced Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSC…

Non Small Cell Lung CancerAdvanced Non Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+1 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Regeneron PharmaceuticalsNCT07154290

Phase 4

Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study

This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development,…

MelanomaNon Small Cell Lung CancerSolid Tumor+2 more

Estimated

~$25 – $1,400

Actual pay is set by the research site.

Novartis PharmaceuticalsNCT03340506

Observational

Rise & Thrive: Community-Engagement Intervention to Address Chronic Stress and Prevent Depression in Adolescents and Young Adults

American youth and young adults face persistent and chronic stressors, which have contributed to a mental health crisis in the United States. Four in 10 Americ…

Depressive SymptomsAllostatic LoadMetabolic Syndrome

Estimated

~$10 – $750

Actual pay is set by the research site.

Ann & Robert H Lurie Children's Hospital of ChicagoNCT07554326

Phase 1

A Phase Ib/II, Multi-site, Open-label, Dose Finding Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT326 in Combination With BNT327 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pumitamig (also known as …

Non-small Cell Lung Cancer

Estimated

~$150 – $4,500

Actual pay is set by the research site.

BioNTech SENCT07111520

Phase 2

A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease …

Non-Small Cell Lung Cancerc-MET

Estimated

~$75 – $3,000

Actual pay is set by the research site.

AbbVieNCT06568939

Observational

6-Hz Primed Low and High-Frequency Repetitive Transcranial Magnetic Stimulation on Motor Function and Meta-Plasticity in Children With Cerebral Palsy: TMS-EEG Study

This project examines the use of repetitive transcranial magnetic stimulation (rTMS) as a therapeutic approach to improve motor function in children with cereb…

Cerebral PalsyTypically Developing Children

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Cook Children's Health Care SystemNCT07567053